Premedication after grade 1 infusion reaction

Vantrexa · Metastatic NSCLC

MI-2026-0063UrgentArchivedBreachedSafety

RARachel AdeyemiMSL, Oncology (UK & Ireland)

Restricted — potential adverse event

Access limited to Medical Information and Safety roles. Details are captured minimally and routed to pharmacovigilance per SOP-PV-014. AI features are disabled for this record (PRD §27.7).

Received: 22 May 2026, 08:43 UTC
Channel: Congress booth
Requestor type: Payer
Country / region / team: United States · North America · MI Americas
Category: Safety
Response type: Custom response
Owner: RARachel Adeyemi
Due: 24 May 2026, 08:43 UTC
Responded: 26 May 2026, 20:43 UTC
Quality review: Passed
Related insight: —
Related standard response: None matched (topic-keyword match)

Workflow

12-stage inquiry workflow (PRD §16). Advancing records an audit event.

Received
Triage
Assigned
In progress
Escalated
Draft response
Medical review
Quality review
Sent
Follow-up required
Closed
12Archived

Current stageArchivedDemo action — not persisted

SLA

Urgent: 48 h target · Routine 120 h / Urgent 48 h / Critical 24 h

SLA hours

Elapsed

108 h

to response

Breached by

60 h

100%

Timeline

22 May 2026, 08:43 UTC
Received via Congress booth
Payer · United States
22 May 2026, 08:43 UTC
Triage and assignment
Urgency Urgent · assigned to MI Americas
24 May 2026, 08:43 UTC
SLA due (48 h)
26 May 2026, 20:43 UTC
Response sent
Custom response · quality review passed

Draft response

Restricted record

AI suggestion disabled — safety-flagged inquiries are not interpreted by AI (PRD §27.7).

Draft response

Audit history

No audit events for this record

Create, update, approve and export events appear here with user, timestamp, previous and new values.

Data lineage: MI inquiry platform (IRMS, INT-05) · received 22 May 2026 · hourly sync.